Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06788938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing
    • Site details revised at 5 of 5 sites
    v12
  2. 2 versions Re-verified since May 5, 2026, no change to tracked fieldsv10-v11
  3. Site details revised at 3 of 5 sitesv9
  4. Site details revised at 1 of 5 sitesv8
  5. Site contacts updated at 1 of 5 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 4 to 5v6
  2. Site contacts updated at 4 of 4 sitesv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 1, 2025 to Mar 21, 2025
    • Site details revised at 4 of 4 sites
    v4
  4. Start date: Mar 1, 2025 to Apr 1, 2025
    • Primary completion date: Sep 24, 2028 to Apr 24, 2028
    • Study completion date: Sep 24, 2029 to Apr 24, 2029
    • Site contacts updated at 1 of 4 sites
    v3
  5. Secondary endpoints: details revised at 1 of 4 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Trial Details
NCT Number NCT06788938
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Amgen
Conditions
(from sponsor)		 DLL3-expressing Tumors, Advanced Tumors
Related terms Neoplasms
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov